Gender-specific challenges in the management of epilepsy in women

Seminars in Neurology

Volumn 27, Issue 4, 2007, Pages 331-339

  Noe, Katherine H ^a  

^a MAYO CLINIC HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Catamenial epilepsy; Contraception; Pregnancy; Teratogenesis

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CALCIUM; CARBAMAZEPINE; ETHINYLESTRADIOL; FOLIC ACID; LAMOTRIGINE; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PROGESTERONE; SEX HORMONE; VALPROIC ACID; VITAMIN D;

ADULT; BIRTH CONTROL; BREAST FEEDING; CASE REPORT; CATAMENIAL EPILEPSY; CONGENITAL MALFORMATION; CONTRACEPTION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MEGADOSE; EPILEPSY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MEDICAL SPECIALIST; MENOPAUSE; OSTEOPOROSIS; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPRODUCTIVE HEALTH; REVIEW; SEX DIFFERENCE; SEXUAL HEALTH; TERATOGENICITY;

ADULT; EPILEPSY; FEMALE; GONADAL STEROID HORMONES; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; REPRODUCTION; WOMEN'S HEALTH;

EID: 34548356551     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985335     Document Type: Review

References (77)

1. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy. Neurology 1998;51:944-948
2. Seale CG, Morrell MJ, Nelson L, Druzin ML. Analysis of prenatal and gestational care given to women with epilepsy. Neurology 1998;51:1039-1045
3. Morrell MJ, Sarto GE, Shafer PO, Borda EA, Herzog A, Callanan M. Health issues for women with epilepsy: a descriptive survey to assess knowledge and awareness among healthcare providers. J Womens Health Gend Based Med 2000;9:959-965
4. Long L, Mantouris G. Knowledge of women's issues and epilepsy (KOWIE-II), a survey of healthcare professionals. Epilepsy Behav 2005;6:90-93
5. Klein P, van Passel-Clark LM, Pezzullo JC. Onset of epilepsy at the time of menarche. Neurology 2003;60:495-497
6. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997;38:1082-1088
7. Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization related epilepsy. Ann Neurol 2004;56:431-434
8. Scharfman HE, MacLusky NJ. The influence of gonadal hormones on neuronal excitability, seizures, and epilepsy in the female. Epilepsia 2006;47:1423-1440
9. Morrell MJ, Giudice L, Flynn KL, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol 2002;52:704-711
10. Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy. Epilepsia 2001;42:746-749
11. Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology 1984;34:1255-1258
12. Herzog AG. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 1995;45:1660-1662
13. Herzog AG. Progesterone therapy in women with epilepsy: a three year follow-up. Neurology 1999;52:1917-1918
14. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972;2:839-843
15. Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003;61(suppl 2):S23-S26
16. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-158
17. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in the offspring of women with epilepsy. Neurology 2003;60:575-579
18. Morrow J, Russell A, Guthrie E, et al. Malformation risk of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-198
19. Artama M, Ritvanen A, Gissler M, Isojarvi J, Auvinen A. Congenital structural anomalies in offspring of women with epilepsy: a population based cohort study in Finland. Int J Epidemiol 2006;35:280-287
20. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population based register study. Acta Paediatr 2004;93:174-176
21. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-965
22. Vajda FJ, Eadie MJ. Maternal valproate dosage and fetal malformations. Acta Neurol Scand 2005;112:137-143
23. Vajda FJ, Hitchcock A, Graham J, et al. Fetal malformations and seizure control: 52 months of data of the Australian Pregnancy Registry. Eur J Neurol 2006;13:645-654
24. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-1583
25. Holmes LB, Wyszynski DR, Baldwin EJ, Haebecker E, Glassman LH, Smith CR. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy [abstract]. Birth Defects Res Part A Clin Mol Teratol 2006;76:318
26. Samren EB, van Duijn CM, Kock S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-990
27. Yerby MS, Kaplan P, Tran T. Risks and management of pregnancy in women with epilepsy. Cleve Clin J Med 2004;71(suppl 2):S25-S37
28. EURAP Investigators. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006;66:354-360
29. Teramo K, Hiilesmaa VK. Pregnancy and fetal complications in epileptic pregnancies: review of the literature. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D, eds. Epilepsy, Pregnancy and the Child. New York: Raven Press; 1982:53-59
30. Teramo K, Hiilesmaa V, Saarikoski AB. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 1979;7:3-6
31. Nei M, Daly S, Liporace J. A maternal partial complex seizure in labor can affect fetal heart rate. Neurology 1998;51:904-906
32. Sahoo S, Klein P. Maternal complex partial seizure associated with fetal distress. Arch Neurol 2005;62:1304-1305
33. Centers for Disease Control. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992;41:1-7
34. Section of Breastfeeding, American Academy of Pediatrics. Breastfeeding and the use of human milk. Pediatrics 2005;115:496-506
35. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24-29
36. Fairgrieve SD, Jackson M, Jonas P, et al. Population based prospective study of the care of women with epilepsy in pregnancy. BMJ 2000;321:674-675
37. Krauss GL, Brandt J, Cambell M, Plate C, Summerfield M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologist and obstetricians. Neurology 1996;46:1534-1539
38. Bensyl DM, Iuliano DA, Carter M, Santelli J, Gilbert BC. Contraceptive use: United States and territories, behavioral risk factor surveillance system, 2002. MMWR Surveill Summ 2005;54:1-72
39. O'Brien MD, Guillebaud J. Contraception for women with epilepsy. Epilepsia 2006;47:1419-1422
40. Thorneycroft I, Klein P, Simon J. The impact of antiepileptic drug therapy on steroidal contraceptive efficacy. Epilepsy Behav 2006;9:31-39
41. Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology 2006;67(suppl 4):S56-S58
42. De Souza A, Brechin S, Penney G. The member's enquiry service: frequently asked questions. J Fam Plann Reprod Health Care 2004;30:57-58
43. Bounds W, Guillebaud J. Observational series on women using contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plann Reprod Health Care 2002;28:78-80
44. Dirubbo NE. Counsel your patients about contraceptive options. Nurse Pract 2006;31:40-44
45. Sabers A, Ohman I, Christensens J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-571
46. Klein P, Serje A, Pezzullo JC. Premature ovarian failure in women with epilepsy. Epilepsia 2001;42:1584-1589
47. Harden CL, Koppel BS, Herzog AG, et al. Seizure frequency is associated with age at menopause in women with epilepsy. Neurology 2003;61:451-455
48. Harden CL, Pulver MC, Ravdin L, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999;40:1402-1407
49. Abbasi F, Krumholz A, Kittner SJ, Langenberg P. Effects of menopause on seizures in women with epilepsy. Epilepsia 1999;40:205-210
50. Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613
51. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
52. Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized double-blind placebo-controlled study. Epilepsia 2006;47:1447-1451
53. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Office of Surgeon General; 2004
54. Empana JP, Dargent-Molina P, Breart G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 2004;52:685-690
55. Valmadrid C, Voorhees C, Litte B, Schneyer C. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001;58:1369-1374
56. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-773
57. Van Staa TP, Leufkens HG, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone 2002;31:508-514
58. Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999;99:269-275
59. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004;45:1330-1337
60. Souverein PC, Webb DJ, Petri H, Weil J, Van Staa TP, Egberts T. Incidence of fractures among epilepsy patients: a population-based prospective cohort study in the General Practice Research Database. Epilepsia 2005;46:304-310
61. Petty SJ, Paton LM, O'Brien TJ, et al. Effect of antiepileptic medication on bone mineral measures. Neurology 2005;65:1358-1363
62. Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med 2004;71(suppl 2):S42-S48
63. Valimaki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9:631-637
64. Ensrud KE, Walzak TS, Blackwell T, Ensrued ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004;62:2051-2057
65. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57:252-257
66. Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal and postpubertal patients receiving carbamazepine. Epilepsia 2002;43:1488-1492
67. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-262
68. Mintzer S, Bopana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006;47:510-515
69. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-449
70. Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004;50:93-97
71. Burke MS. Current roles and realities of noninvasive assessment of osteoporosis. Curr Opin Endocrinol Diabetes 2004;11:330-337
72. Pack AM, Olarte LS, Morrell MJ, Flaster E, Resor SR, Shane E. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003;4:169-174
73. Farhat G, Yamout B, Mikati A, Demirjian S, Sawaya R, Fuleihan GE. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-1353
74. Binkley N, Bilezikian JP, Kendler DL, et al. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 2006;9:4-14
75. Harden CL. Menopause and bone density issues for women with epilepsy. Neurology 2003;61(suppl 2):S16-S22
76. Mikati MA, Dib L, Yamout B, Sawaya R, Rahi AC, Fuleihan GE. Two randomized vitamin D trials in ambulatory patients on anticonvulsants. Neurology 2006;67:2005-2014
77. Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004;5:S41-S47